All News
Top research stories, including gene regulation and longevity, a head-to-head comparison of COVID-19 vaccines, a newly discovered type of brain cell and more.
Regeneron Pharmaceuticals announced intentions to acquire Sanofi’s stake in a drug they developed together, Libtayo (cemiplimab).
In partnership with the U.S. government, Evonik Industries is investing more than $200 million to build a lipid manufacturing facility in the United States.
Children under the age of five could be eligible to receive Pfizer-BioNTech’s vaccine against COVID-19 as soon as late June.
Researchers at the Earle A. Chiles Research Center have successfully shrunk a woman’s pancreatic cancer tumors using a novel immunotherapy.
Cassava Sciences is reeling after another journal retracted an article co-authored by a key collaborator on its experimental Alzheimer’s disease therapeutic, simufilam.
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
Upstream Bio is focusing its efforts on an experimental treatment for severe asthma licensed from Astellas Pharma.
Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.
Seattle-based Sana Biotechnology is moving on from its current Fremont, California manufacturing facility, inking a lease deal to develop a manufacturing plant in Bothell, Washington.
AstraZeneca CEO Pascal Soriot has been knighted in the Queen’s Birthday Honours for his contribution to life sciences and leadership during the COVID-19 pandemic.
Transition Bio has a four-component platform called Condensomics which provides a technological method to understand the properties of condensates.
Atreca is reducing its staff count by over 25%, covering current employees and open roles, and revising its operating plan to reflect these cost-cutting measures.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
In a recent Massachusetts Biotechnology Council survey, 94.2% of respondents reported having difficulty hiring experienced workers.
A largely untested and unproven treatment for Alzheimer’s disease, called transcranial pulse stimulation (TPS), is becoming popular around the world, although experts are skeptical.
Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.
Shares of TG Therapeutics are falling fast in Wednesday trading after the U.S. Food and Drug Administration announced it was pulling approval of the cancer drug Ukoniq (umbralisib).
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
There are more than 100 known herpesviruses, eight of which infect only humans. Here’s a look at recent stories and research on herpesviruses.